SUPERNUS PHARMACEUTICALS, INC. Other Accounts Payable and Accrued Liabilities
SUPERNUS PHARMACEUTICALS, INC. (SUPN) had Other Accounts Payable and Accrued Liabilities of $56.29 million as of 2020-09-30, per its 10-Q filed 2020-11-06.
Discontinued › Notes › Payables and Accruals
us-gaap:OtherAccountsPayableAndAccruedLiabilities · last filed 2020-11-06
- 2020-09-30: Other Accounts Payable and Accrued Liabilities $56.29M.
- 2020-06-30: Other Accounts Payable and Accrued Liabilities $58.82M.
- 2020-03-31: Other Accounts Payable and Accrued Liabilities $33.00M.
- 2019-12-31: Other Accounts Payable and Accrued Liabilities $34.30M; Other Accounts Payable and Accrued Liabilities as first filed $37.13M.
| Period end | Other Accounts Payable and Accrued Liabilities | Other Accounts Payable and Accrued Liabilities as first filed |
|---|---|---|
| 2020-09-30 | $56.29M 10-Q · filed 2020-11-06 | |
| 2020-06-30 | $58.82M 10-Q · filed 2020-08-17 | |
| 2020-03-31 | $33.00M 10-Q · filed 2020-05-15 | |
| 2019-12-31 | $34.30M 10-Q · filed 2020-11-06 | $37.13M 10-K · filed 2020-02-28 |
| 2019-09-30 | $40.80M 10-Q · filed 2019-11-08 | |
| 2019-06-30 | $38.61M 10-Q · filed 2019-08-09 | |
| 2019-03-31 | $36.61M 10-Q · filed 2019-05-10 | |
| 2018-12-31 | $36.53M 10-K · filed 2020-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |